175 related articles for article (PubMed ID: 31897782)
1. Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors.
Sutton AL; Salgado TM; He J; Hurtado-de-Mendoza A; Sheppard VB
Support Care Cancer; 2020 Sep; 28(9):4147-4154. PubMed ID: 31897782
[TBL] [Abstract][Full Text] [Related]
2. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
3. The role of trust in the acceptance of adjuvant endocrine therapy in breast cancer patients.
Constanze E; Uwe G; Christoph T; Kavitha D; Dominik R; Urte S; Walter B
Psychooncology; 2022 Dec; 31(12):2122-2131. PubMed ID: 36251608
[TBL] [Abstract][Full Text] [Related]
4. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
5. Optimization of an Information Leaflet to Influence Medication Beliefs in Women With Breast Cancer: A Randomized Factorial Experiment.
Green SMC; Hall LH; French DP; Rousseau N; Parbutt C; Walwyn R; Smith SG
Ann Behav Med; 2023 Oct; 57(11):988-1000. PubMed ID: 37494669
[TBL] [Abstract][Full Text] [Related]
6. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
[TBL] [Abstract][Full Text] [Related]
7. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
Toledo G; Ochoa CY; Farias AJ
Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
[TBL] [Abstract][Full Text] [Related]
8. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
[TBL] [Abstract][Full Text] [Related]
9. Correlates of Adjuvant Therapy Attitudes in African American Breast Cancer Patients.
Edmonds MC; Sutton AL; He J; Perera RA; Sheppard VB
J Natl Med Assoc; 2020 Apr; 112(2):167-175. PubMed ID: 32197898
[TBL] [Abstract][Full Text] [Related]
10. Facilitators and barriers to medication adherence with adjuvant endocrine therapy in women with breast cancer: a structural equation modelling approach.
Tan EH; Wong ALA; Tan CC; Wong P; Tan SH; Ang LEY; Lim SE; Chong WQ; Ho J; Lee SC; Tai BC
Breast Cancer Res Treat; 2021 Aug; 188(3):779-788. PubMed ID: 33948777
[TBL] [Abstract][Full Text] [Related]
11. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
[TBL] [Abstract][Full Text] [Related]
12. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
Lambert LK; Balneaves LG; Howard AF; Gotay CC
Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
[TBL] [Abstract][Full Text] [Related]
15. Beliefs about medicines' association with endocrine therapy adherence in early breast cancer survivors in Croatia.
Okroša AD; Silovski T; Plavetić ND; Silovski H; Kovačić A; Mucalo I
Acta Pharm; 2023 Dec; 73(4):673-689. PubMed ID: 38147479
[TBL] [Abstract][Full Text] [Related]
16. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
[TBL] [Abstract][Full Text] [Related]
17. Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence.
Wouters H; van Geffen EC; Baas-Thijssen MC; Krol-Warmerdam EM; Stiggelbout AM; Belitser S; Bouvy ML; van Dijk L
Breast; 2013 Oct; 22(5):661-6. PubMed ID: 23770134
[TBL] [Abstract][Full Text] [Related]
18. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
19. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
20. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
